Skip to main content Skip to search Skip to main navigation
News: Europa

EU GMP Guide: Chapter 4, Annex 11 and New Annex 22

The EC has published the long-awaited revised and new documents of the EU GMP Guide for consultation: Chapter 4 Documentation, Annex 11 Computerised Systems and the new Annex 22 Artificial Intelligence. Stakeholder consultations are open until 7 October on the EC website.

Revision of Chapter 4 – Documentation

The updated Chapter 4 emphasises the critical role of documentation in GMP and supports the use of digital, hybrid, and emerging technologies. Risk-based data governance is now a core element to ensure document accuracy, integrity, availability, and legibility across all formats. It also clarifies requirements for managing electronic records, signatures, and data integrity, aligning with the ongoing revision of Annex 11.

Revision of Annex 11 – Computerised Systems

The updated Annex 11 reinforces lifecycle management of computerised systems, requiring comprehensive application of Quality Risk Management. It strengthens requirements for system specifications, supplier oversight, data integrity, audit trails, electronic signatures, and security.

New Annex 22 – Artificial Intelligence

Annex 22 sets out requirements for the use of AI and machine learning in the manufacture of active substances and medicinal products. It covers model selection, training, validation, and performance monitoring. Key areas include intended use, data quality, performance metrics, change control, and human oversight.


Source:

EC: Public Health/Consultations/ Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA has revised its framework for collaboration between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). Version 2.0 of the Concept of Operations (ConOps), effective October 21, 2026, supersedes the original June 2017 version.
Read more
Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

For any outsourced GDP activity, there is a need for delimitation of responsibilities between a client (contract giver) and a contractor (contract acceptor). Read more about their roles and responsibilities in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

Who is Qualified to Conduct Self-Inspections within a Company?

Here's the question:
Read more
News: Europe

EU: Singapore Added to List of Recognised Third Countries for API Importation

The European Commission recognises Singapore’s GMP requirements and regulatory oversight of active substance manufacturers as equivalent to EU requirements. Once the decision enters into force (15 November), Singapore will join the EU list of recognised third countries for the importation of active substances.
Read more
PIC/S/EMA/WHO: New Q&A on Annex 1

PIC/S/EMA/WHO: New Q&A on Annex 1

The revision of Annex 1 also made it necessary to update the previous PIC/S interpretation document, PI 032-2, “GMP Annex 1 Revision 2008, Interpretation of Most Important Changes for the Manufacture of Sterile Medicinal Products”. Based on a Swissmedic draft from 2023, the joint PIC/S–EMA–WHO working group developed a new Q&A document.
Read more
News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Previous
Next